or Try an Advanced Search...

    Technical Analysis for CABA - Cabaletta Bio, Inc.

    Grade Last Price % Change Price Change
    F 11.23 -0.27% -0.03
    CABA closed down 0.27 percent on Tuesday, May 14, 2024, on 38 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical CABA trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    NR7 Range Contraction -0.27%
    Inside Day Range Contraction -0.27%
    Wide Bands Range Expansion -0.27%
    Earnings Movers Other -0.27%
    Wide Bands Range Expansion -0.27%
    Earnings Movers Other -8.10%
    Inside Day Range Contraction -8.10%
    Older End-of-Day Signals for CABA ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 17 hours ago
    Down 1% about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    Up 3% about 21 hours ago
    Up 2% about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CABA Chart by TradingView
    Basic chart:

    Profile

    Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Immunology Antibodies Autoimmune Disease Autoimmunity T Cell Sjögren Syndrome

    Is CABA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 13 Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
    May 5 Wall Street Breakfast: The Week Ahead
    Mar 23 Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway
    Mar 21 Cabaletta Bio files automatic mixed securities shelf
    Mar 21 Cabaletta Bio GAAP EPS of -$0.46
    Mar 21 Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    Mar 20 Cabaletta gets FDA orphan drug status for systemic sclerosis drug
    Mar 20 Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
    Mar 8 Jim Cramer’s 10 Latest Stock Picks This Week
    Mar 6 Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
    See more CABA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 26.35
    52 Week Low 9.02
    Average Volume 1,234,997
    200-Day Moving Average 17.21
    50-Day Moving Average 15.95
    20-Day Moving Average 12.37
    10-Day Moving Average 12.11
    Average True Range 1.04
    RSI (14) 31.97
    ADX 33.5
    +DI 14.40
    -DI 30.30
    Chandelier Exit (Long, 3 ATRs) 14.44
    Chandelier Exit (Short, 3 ATRs) 12.86
    Upper Bollinger Bands 14.66
    Lower Bollinger Band 10.09
    Percent B (%b) 0.25
    BandWidth 36.95
    MACD Line -1.31
    MACD Signal Line -1.43
    MACD Histogram 0.1215
    Fundamentals Value
    Market Cap 481.2 Million
    Num Shares 42.8 Million
    EPS -1.70
    Price-to-Earnings (P/E) Ratio -6.61
    Price-to-Sales 0.00
    Price-to-Book 6.65
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.13
    Resistance 3 (R3) 12.18 11.94 11.98
    Resistance 2 (R2) 11.94 11.71 11.91 11.93
    Resistance 1 (R1) 11.58 11.57 11.46 11.53 11.88
    Pivot Point 11.34 11.34 11.28 11.31 11.34
    Support 1 (S1) 10.98 11.11 10.86 10.93 10.58
    Support 2 (S2) 10.74 10.97 10.71 10.53
    Support 3 (S3) 10.38 10.74 10.48
    Support 4 (S4) 10.33